Home / Products / Polyclonal antibody /

Parkin Polyclonal Antibody

Product code: YP-Ab-12790
Promotional price:

Product introduction

Reactive species
Human;Mouse;Rat;Chicken
Applications
WB;IHC;IF;ELISA
Antibody type
Polyclonal Antibody
Gene Name
PARK2
Protein name
E3 ubiquitin-protein ligase parkin
Dalton(DA)
55kD
Immunogen
The antiserum was produced against synthesized peptide derived from human Parkin. AA range:101-150
Specificity
Parkin Polyclonal Antibody detects endogenous levels of Parkin protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
WB: 1/500 - 1/2000. IHC: 1/100 - 1/300. ELISA: 1/10000.. IF 1:50-200
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Stockpile
-20°C/1 year
Other name
PARK2; PRKN; E3 ubiquitin-protein ligase parkin; Parkinson juvenile disease protein 2; Parkinson disease protein 2
Background
The precise function of this gene is unknown; however, the encoded protein is a component of a multiprotein E3 ubiquitin ligase complex that mediates the targeting of substrate proteins for proteasomal degradation. Mutations in this gene are known to cause Parkinson disease and autosomal recessive juvenile Parkinson disease. Alternative splicing of this gene produces multiple transcript variants encoding distinct isoforms. Additional splice variants of this gene have been described but currently lack transcript support. [provided by RefSeq, Jul 2008],
Function
disease:Defects in PARK2 are a cause of Parkinson disease (PD) [MIM:168600]. PD is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology of PD involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain.,disease:D

Open

Product Details

Customer data and reviews (0)

Fold content

Citation

Fold content

Experimental scheme

Fold content
>